| Zytoprotec–Baxter: investment, 201301 financing €2m from new investor Baxter Ventures |
2013-01-29 |
| Zürcher Kantonalbank–Bellevue: investment, 201409– acquisition 100% of Adamant Biomedical Investments AG from ZKB |
2014-09-05 |
| Zymeworks–Minapharm: GlymaxX technology, 201510– supply service cell line development for bispecific antibody production applying GlymaxX by ProBioGen |
2015-10-14 |
| Zweckverband Landeswasserversorgung–Danaher: mass spectrometer, 201012– supply AB Sciex TripleTOF 5600 to Waterworks Langenau + collab method developm |
2010-12-08 |
| Zivak Technologies–Tecan: automated liquid handling, 201310 supply Cavro Omni Robot for use with clinical Dx HPLC + LC-MSMS systems |
2013-10-22 |
| Zinsser Analytic–Kohlberg Kravis Roberts: investment, 201609 acquisition of ILS Gmbh + Zinsser Analytic GmbH from Mr+Ms Zinsser by Gardner Denver |
2016-09-01 |
| Zinc Ahead–Veeva Systems: investment, 201509 acquisition $130m in cash incl $10m deffered consideration over 3 years |
2015-09-29 |
| ZIM Plant Technology–Yara: investment, 201311–201401 acquisition by Yara |
|
| ZIM Plant Technology–High-Tech Gründerfonds: investment, 201204 investment by HTGF |
2012-04-04 |
| Ziarco–Novartis: investment, 201612 acquisition €na by Novartis ANNOUNCED |
2016-12-16 |
| Zespri–Metabolomic Discoveries: metabolomic services, 201601– supply service MS-based profiling of kiwi fruit using Flavour Profiler Technology |
2016-01-18 |
| Zernike–Bremen (govt): grant, 201008 investment €9.6m for opening up for development the estate for Jacobs Science Park JUST |
2010-08-31 |
| Zeltia–Scienion: DNA microarrays, 201211– collab expansion product integration to provide molecular microarray solutions Genomia SAU |
2012-11-05 |
| Zellkraftwerk–MHH: Switch-Antibodies technology, 201510– license ww excl to Zellkraftwerk GmbH from MHH |
2015-10-20 |
| Zellkraftwerk–Helmholtz: investment, 201510 Ascenion acquires equity position under license agreem with MHH for Switch-Antibodies technology |
2015-10-20 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| Zedira–Univ Marburg: structural biology, 201502 collab existent w group of Prof Gerhard Klebe |
2015-02-03 |
| Zedira–R-Biopharm: investment, 201206 existing investor is R-Biopharm AG |
2012-06-22 |
| Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy |
2016-11-30 |
| Zedira–Germany (govt): grant, 201502– BMBF funding €1m to support further coagulation factor XIIIa inihibitor development |
2015-02-03 |
| Zedira–Cardiff Univ: drug discovery, 201509– collab research role of transglutaminase 6 in disease pathway of cerebellar ataxia |
2015-09-22 |
| Zavante Therapeutics–SEVERAL: investment, 201603 financing round Series A $45m with $35m from new investors + $10m conversion of convertible notes |
2016-03-30 |
| Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones |
2018-07-24 |
| Yumda–Chemie.DE: investment, 201704 acquisition of Yumda GmbH by Chemie.DE Information Service GmbH |
2017-04-01 |
| Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi |
2019-06-04 |
| Yuhan–Cevec: CAP technology, 201212– license to use CAP + CAP-T cell expression systems therapeutic protein developm + production |
2012-12-20 |
| YES Pharma Services–Auctus Capital: investment, 201410 acquisition of majority share by funds advised by Auctus Capital Partners AG |
2014-10-22 |
| Xtal Concepts–Hamburg (govt): investment, 201207 investment in Xtal Concepts GmbH by Innovationsstarter Fonds Hamburg |
2012-07-16 |
| Xradia–Carl Zeiss: investment, 201306–201307 acquisition of Xradia Inc renamed Carl Zeiss X-ray Microscopy Inc |
2013-06-13 |
| Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares |
2016-12-19 |
| Xiril–Sias: investment, 2012 acquisition of Xiril AG by Sias AG |
2012-01-01 |
| Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners |
2017-01-05 |
| Xenikos–MC Services: public relations, 201605 service existent for Xenikos BV by MC Services AG Düsseldorf |
2016-05-24 |
| Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies |
2016-11-03 |
| Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies |
2011-01-01 |
| Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies |
2018-02-26 |
| Xencor–Boehringer: rec protein production, 201202– service + collab developm + manufacture + supply of mABs using Xtend technology for Xencor |
2012-02-21 |
| Xeltis–VI Partners: investment, 201412 financing round Series B totalling €27m incl co-investor VI Partners |
2014-12-02 |
| Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al |
2017-11-15 |
| Xeltis–SEVERAL: investment, 201512 financing round Series B extension €3m bringing total Series B to €30m |
2015-12-17 |
| Xeltis–SEVERAL: investment, 201412 financing round Series B €27m co-led by LSP + Kurma Partners plus VI Partners + current investors |
2014-12-02 |
| Xeltis–Life Sciences Partners: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners |
2014-12-02 |
| Xeltis–Kurma: investment, 201412 financing round Series B totalling €27m co-led by LSP + Kurma Partners |
2014-12-02 |
| X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED |
2018-11-27 |
| X-Zyme–Johnson Matthey: investment, 201007 acquisition |
2010-07-05 |
| WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Wise (IT)–SEVERAL: investment, 201705 financing round Series B €6.5m led by Prinicpia SGR + incl Atlante Ventures + HTGF + F3F + Antares |
2017-05-25 |
| Wiley–Medical Univ Innsbruck: MSforID Library, 201106 collab Wiley publishes MSforID as Wiley Registry of Tanden Mass Spectral Data |
2011-06-14 |
| Wiley–GeneBio: SmileMS software, 201105– collab ww non-excl co-distribution of SmileMS with LC-MS/MS libraries |
2011-05-30 |
| Wilex–Yorkville Group: investment, 201003– standby equity line up to $20m new shares to be purchased within 3y by YA Global Master SPV on request |
2010-03-23 |
| Wilex–UCB: credit, 201012–201405 subordinated loan up to €2.5m interest rate 6% annual from UCB Pharma SA REPAYMENT WAIVED 5/14 |
2010-12-17 |
| Wilex–SEVERAL: investment, 201704– capital increase €4.99m with rights issue to existing shareholders incl dievini Hopp |
2017-04-24 |
| Wilex–SEVERAL: investment, 201604 capital increase €4.13m with 2.25m new shares at €1.84/share whereof >50% to Dievini Hopp |
2016-04-25 |
| Wilex–SEVERAL: investment, 201512 investment €815k w 443,124 new shares at €1.84/share to existent shareholders |
2015-12-09 |
| Wilex–SEVERAL: investment, 201504 capital increase €4.16m with 1.5m new shares €2.8/share |
2015-04-07 |
| Wilex–SEVERAL: investment, 201201–201202 capital increase €9.93m with 3.2m new authorised shares €3.1/share |
2012-01-09 |
| Wilex–SEVERAL: investment, 201007–201008 private placement €10m 2.46m new shares €4.1/share to existing investors incl Hopp + UCB |
2010-07-19 |
| Wilex–Nuclea Biotechnologies: investment, 201309 acquisition 100% of Wilex Inc by Nuclea w repayment $2.5m interfirm loan + $2.5m services + royalties |
2013-09-06 |
| Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] |
2017-02-06 |
| Wilex–Hopp Group: investment, 201512 investment €1.712m w 930,560 new shares at €1.84/share dievini Hopp BioTech holding |
2015-12-09 |
| Wilex–Hopp Group: credit, 201012– subordinated loan up to €7.5m interest rate 6% annual from Dievini Hopp BioTech Holding GmbH & Co KG |
2010-12-17 |
| Wilex–Germany (govt): grant, 201202– BMBF funding of up to €2.6m for developm of WX-037 within m4 Cluster Initiative |
2012-02-06 |
| Westburg–Medicyte: cell technology, 201302– distribution of upcyte + vericyte technology + products in Benelux by Westburg BV |
2013-02-13 |
| Westburg–Analytik Jena: investment, 201107 acquisition 20% stake in Westburg BV for €150k |
2011-07-18 |
| Werum–Körber: investment, 201402– acquisition of newly formed Werum IT Solutions AG by Körber Medipak |
2014-02-10 |
| Werfen–Protagen: biomarker, 201608– license semi-excl for use of BICD2 biomarker for diagnosis of systemic sclerosis to Inova Diagnostics |
2016-08-11 |
| Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO |
2019-07-31 |
| Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company |
2019-07-31 |
| Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx |
2019-07-31 |
| Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB |
2019-07-31 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital |
2019-07-31 |
| Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF |
2019-07-31 |
| Wellington Partners–Consilium: public relations, 201907 service existent by CSC |
2019-07-31 |
| Wellington Partners–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D |
2018-11-01 |
| Weizmann Institute–XL-protein: PASylation technology, 201410– Yeda acquires ww excl marketing + outlicensing rights to PAS-YNSa8 dev by XL + Weizmann |
2014-10-21 |
| Weizmann Institute–Bruker: MRI system, 201710 supply Biospec 15.2 Tesla USR preclinical UHF MRI system |
2017-10-18 |
| WeissBioTech–BRAIN: investment, 201411 acquisition €na of majority shareholding in WeissBioTech GmbH by BRAIN AG |
2014-11-27 |
| WBM Health Science–Medicyte: cell technology, 201306– collab promotion of Medicyte products + services in India by WBM |
2013-06-25 |
| Waters–Tecan: liquid handling technology, 201201– supply €na OEM Freedom EVO platform for Waters clinical lab assays with ACQUITY TQD LS/MS/MS |
2012-01-17 |
| Waters–Biocrates: AbsoluteIDQ Kits, 201205– collab Waters Xevo TQ MS editions of established AbsoluteIDQ p180 + p150 kits |
2012-05-14 |
| Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research |
2019-02-06 |
| Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution |
2017-06-01 |
| Warp Drive Bio–Revolution Medicines: investment, 201810 acquisition of Warp Drive Bio by Revolution Medicines |
2018-10-16 |
| Wagner Analysen Technik–Orexo: investment, 201107 acquisition €1.4m + milestones by Kibion AB |
2011-07-14 |
| Wageningen Univ–Thermo Fisher: mass spectrometer, 201511 supply existent use of Q Exactive GC system by Marc Tienstra at RIKILT |
2015-11-03 |
| Wageningen Univ–Thermo Fisher: mass spectrometer, 201503 supply existent Hans Mol RIKILT Wageningen UR early access user of Q Exactive Focus |
2015-03-09 |
| VTU–Univ Oxford: recombinant protein production, 201109 collab existent Univ Oxford is partner of VTU Technology GmbH |
2011-09-13 |
| VTU–TU Graz: recombinant protein production, 201109 collab existent Graz Univ of Technology is partner of VTU Technology GmbH |
2011-09-13 |
| VTU–KonValue: investment, 201810 acquisition of VTU Technology by KonValue Group from VTU Holding GmbH + renaming as Validogen GmbH |
2018-10-22 |
| VTU–ACIB: recombinant protein production, 201109 collab existent ACIB is partner of VTU Technology GmbH |
2011-09-13 |
| Volution Immuno Pharmaceuticals–Celsus Therapeutics: investment, 201508– reverse merger acqu of VIP by Celsus to be renamed Akari Therapeutics |
2015-07-13 |
| Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-08 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG |
2019-10-08 |
| Vivoryon–MC Services: public relations, 201910 service existent by MC Services |
2019-10-08 |
| vivoPharm–Protea Biosciences: investment, 201503–201601 acquisition $12m in cash + shares subject to raising necessary financing NOT REALISED |
2015-03-31 |
| Vividion Therapeutics–SEVERAL: investment, 201904 financing round Series B $82m led by new investor Nextech Invest |
2019-04-30 |
| Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest |
2019-04-30 |
| Vivet Therapeutics–Ysios Capital: investment, 201705 financing round Series A totalling €37.5m incl co-investor Ysios Capital |
2017-05-04 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
